Residual or Recurrent Grade 2 IDH Mutant Glioma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Residual or Recurrent Grade 2 IDH Mutant Glioma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Active — Not RecruitingPhase 3

NCT06780930

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an ID…

The objective of this study is to determine the efficacy, safety, and pharmacokinetics of vorasidenib in Asian participants with residual or recurrent Grade 2 g…

China57 participantsStarted 2024-10-18

Treatment: Vorasidenib, Placebo